PLK1 Cancer Research Results

PLK1, Polo-like kinase 1: Click to Expand ⟱
Source:
Type:

Polo-like kinase 1 (PLK-1) is a mitotic serine/threonine kinase and high-value cancer target. It is commonly upregulated in proliferative malignancies and supports G2/M progression, spindle formation, chromosome segregation, cytokinesis, DNA-damage recovery, and survival of genomically unstable tumor cells. Inhibition of PLK1 can induce mitotic arrest, apoptosis, and sensitization to chemotherapy or radiotherapy. Clinical development has been challenging due to toxicity and limited single-agent efficacy with earlier inhibitors, but newer agents such as onvansertib show renewed promise, particularly in RAS/KRAS-mutant metastatic colorectal cancer.



Scientific Papers found: Click to Expand⟱
6451- SAO,    α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer
- vitro+vivo, BC, MDA-MB-231
TumCP↓, selectivity↑, Bcl-2↓, PLK1↓, BAD↑, Casp↑, BAX↑, Dose↝, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned

PLK1↓, 1,  

Cell Death

BAD↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,  

Proliferation, Differentiation & Cell State

TumCG↓, 1,  

Migration

TumCP↓, 1,  

Drug Metabolism & Resistance

Dose↝, 1,   selectivity↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PLK1, Polo-like kinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1492  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page